Meldoxon (Meldonium Dihydrate)

Meldonium blocks the enzyme γ‑butyrobetaine hydroxylase, which reduces the synthesis of carnitine. Lower carnitine levels shift myocardial energy production from fatty‑acid oxidation to glucose oxidation, a pathway that uses less oxygen per unit of ATP. This metabolic shift enhances cardiac performance during periods of limited oxygen supply.

The specific dose of Meldoxon is determined by the prescribing clinician based on the individual’s medical condition, severity, and response to therapy. Healthcare providers tailor the regimen to each patient, and the exact amount and frequency should be obtained from the prescriber’s instructions.

Safety data for Meldoxon in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare professional.

To place an order, submit an enquiry on the Meldoxon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Meldoxon differs from traditional anti‑ischemic drugs such as nitrates or beta‑blockers by targeting cellular metabolism rather than vascular tone. Compared with trimetazidine, another metabolic modulator, Meldoxon primarily reduces carnitine synthesis, whereas trimetazidine inhibits fatty‑acid β‑oxidation directly. Both aim to improve myocardial efficiency, but their mechanisms and side‑effect profiles are distinct.

Meldoxon tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in humid environments or near sources of heat, and keep the container tightly closed when not in use.

Meldoxon is taken orally, usually with a glass of water. It can be administered with or without food, but patients should follow the prescribing clinician’s guidance regarding timing relative to meals to ensure consistent absorption.

The most serious adverse reactions reported with Meldoxon include severe hypotension, allergic responses such as rash or swelling, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience sudden drops in blood pressure, signs of an allergic reaction, or irregular heartbeats.

Meldoxon is contraindicated in patients with known hypersensitivity to meldonium or any excipients in the tablet. It should also be avoided in individuals with uncontrolled hypertension, severe hepatic impairment, or those taking other agents that markedly affect carnitine metabolism without medical supervision.